ADSI is the home and center of the Phytovalley Tyrol and part of an international science hub specialized in plant biotechnology. In the sense of translational research, industry and science jointly explore the treasures of nature with the goal of providing safe and effective natural products.

Throughout the last decade in Innsbruck a strong emphasis on cell biology, oncology, as well as on proteomics and analytical chemistry has evolved in basic research. These developments have been completed by industry related applied research in the Center for personalized Cancer Medicine Oncotyrol, GEN-AU and EU research proteomics in proteomics, and oncology. A particular highlight has been the longstanding cooperation with Bionorica Research GmbH.



The Bavarian phytopharma company Bionorica, is one of the world’s leading producers of plant derived pharmaceuticals. In 2017 Bionorica strengthened its cooperation with the University of Innsbruck. Professor Michael A. Popp, chairmen of Bionorica SE, and the state of Tyrol invested a total of 5 million Euro into the competence center for phytoresearch. The newly founded Michael-Popp-Institute for plant derived active substance research now investigates new therapy options for widely spread diseases. Professor Andreas Koeberle, a renowned expert in the field, was appointed director of the new institute.

More than 20 scientists are employed at this institute featuring state of the art equipment. An additional professorship for “plant derived biotechnology” was also established, with further expansions planned in the future through the raising of external funds. The Michael-Popp-Institute is therefore among the biggest research infrastructures, in the field of plant derived pharmaceuticals, in Austria.

Translational Research

The main goals are new therapeutic methods for chronical inflammatory diseases, metabolic diseases like diabetes, and cancer. An extensive institute laboratory of roughly 200m2 was equipped with modern, state of the art analytical devices. One of the most powerful mass-spectrometer currently available stands at the heart of this laboratory.

Interconnectivity between economics and science are the key to the further development of the research site and the creation of highly qualified jobs.

Huge Potential for Various Applications

With additional funding, the Science Hub Phytovalley was able to strengthen its leading position and competence in phyto research. The entirety of the value chain, from basic to applied research, all the way to production, can now be covered within the region. Furthermore, concrete plans have been made for the cultivation of test plants for medicinal use, under the foundation of a second endowment professorship.

Even now, over a 100 scientists are conducting research into new active ingredients from nature, at the institute for analytical chemistry and pharmaceuticals at the University of Innsbruck and at the Austrian Drug Screening Institute (ADSI). Only around 5-10% of the around 400,000 plants worldwide, have been chemically analyzed. This means that there is huge potential for new discoveries and variety of new applications.

Bionorica Invests 40 Million Euros

Bionorica’s subsidiary company, Bionorica Research GmbH, was established in Innsbruck in 2005, and has since invested over 40 million euros into research in to Phytovalley. 140 new jobs will be generated at this location in Innsbruck. The newly founded research institution is privately funded by the Michael A. Popp Nature Science Foundation and the state of Tyrol.

Sei kein Gefangener der Vergangenheit:
Internet Explorer ist für unsere Technologie zu alt!
Bitte verwende einen der folgenden Browser!